In this article, we will discuss: 8 Best Genomics Stocks to Buy According to Analysts.
On June 8, 2026, Google DeepMind, Google.org, and the Wellcome Sanger Institute announced a five-year artificial intelligence collaboration for genomics. The partners said they will generate large-scale, artificial intelligence-friendly genomic datasets to address data gaps and train next-generation biological models to make biology more predictive. Dr. Julia Wilson, Chief Innovation and Impact Officer at the Sanger Institute, said the initiative combines “world-leading datasets” with AI expertise that will speed up biological data generation for shared scientific use.
As per the statement, the team will develop a framework for training AI models in genomics and encourage new collaborators to promote participation. Dr. Pushmeet Kohli, Vice President of AI for Science at Google DeepMind, stated that the project will create “the data backbone needed to decode the complexities of biological processes.” Anna Koivuniemi, Head of the Google DeepMind Impact Accelerator, stated that cross-sector collaboration is required to strengthen AI in genomics. Meanwhile, Leslie Yeh, Director of Google.org Scientific Progress, stated that open-access datasets will allow life-saving scientific advances in global research.
With that said, here are the 8 Best Genomics Stocks to Buy According to Analysts.
Methodology:
To list the 8 Best Genomics Stocks to Buy According to Analysts, we sifted through ETFs and several online rankings and shortlisted the stocks. Next, we chose the ones in which analysts see upside and which are popular among hedge funds as of Q1 2026. We then limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment.
Note: All data was sourced on June 5.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 599.2% since May 2014, beating its benchmark by 372 percentage points (see more details here).
8. Natera, Inc. (NASDAQ:NTRA)
Analysts’ Upside Potential: 22.83%
On June 5, Goldman Sachs initiated coverage on Natera, Inc. (NASDAQ:NTRA) with a Neutral rating and a $245 price target, noting the firm’s leadership in the molecular residual disease testing market. Analyst Evie Koslosky pointed to “strong” commercial execution and a tumor-informed approach resulting in higher sensitivity. Goldman is expecting clearer operating leverage as the company continues reinvesting in growth.
On June 4, Natera, Inc. (NASDAQ:NTRA) announced a collaboration with CytoDyn to evaluate circulating tumor DNA dynamics in metastatic colorectal cancer. Under the agreement, Natera said it will examine CLOVER Phase 2 trial samples using its Signatera assay. It will also deliver real-world data insights drawn from a database exceeding 2 million plasma timepoints.
CytoDyn CEO Jacob Lalezari said the partnership will generate insights into “ctDNA response kinetics and disease progression.” Natera’s Vice President, Biopharma Data & AI Partnering, Matt Love, added that the platform helps partners “better understand disease biology, treatment response, and patient outcomes.”
Natera, Inc. (NASDAQ:NTRA) is a diagnostics company that discovers, develops, and markets genetic testing services. It provides Panorama non-invasive prenatal test, Vistara, horizon carrier screening, spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception, and non-invasive paternity testing.
7. Absci Corporation (NASDAQ:ABSI)
Analysts’ Upside Potential: 40.82%
On June 4, Leerink initiated coverage on Absci Corporation (NASDAQ:ABSI) with an Outperform rating and a $12 price target. The analyst stated that its “AI-native, clinical-stage story” is anchored by lead asset ABS-20 in Phase 1/2 for androgenetic alopecia, with Phase 2 in endometriosis expected to begin in Q4 2026. The firm flagged an “18-month catalyst path” with multiple readouts, calling it highly binary but among the most attractive in its coverage.
Separately, looking forward, Absci Corporation (NASDAQ:ABSI)’s CEO Sean McClain said that 2026 will be a “data-rich year.” He also stated that ABS-201, a long-acting anti-PRLR antibody, could introduce a new mechanism in alopecia with infrequent dosing. The corporation said it completed dosing across four single ascending dose cohorts. It reported favorable safety and PK trends while starting multiple ascending dose cohorts.
The company announced ABS-202, a preclinical anti-PRLR program. It launched an endometriosis advisory board with experts from institutions including Yale, Duke, UCSF, and Mayo Clinic.
Absci Corporation (NASDAQ:ABSI) is a drug and target discovery firm using deep learning AI and synthetic biology to expand the therapeutic potential of proteins.
